ZA913879B - Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy - Google Patents

Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy

Info

Publication number
ZA913879B
ZA913879B ZA913879A ZA913879A ZA913879B ZA 913879 B ZA913879 B ZA 913879B ZA 913879 A ZA913879 A ZA 913879A ZA 913879 A ZA913879 A ZA 913879A ZA 913879 B ZA913879 B ZA 913879B
Authority
ZA
South Africa
Prior art keywords
tumor
chemotherapy
combinations
biologically active
active anti
Prior art date
Application number
ZA913879A
Other languages
English (en)
Inventor
Karl E Hellstrom
E Hellstrom Karl
Ingegerd Hellstrom
Hellstrom Ingegerd
Gary E Goodman
E Goodman Gary
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA913879B publication Critical patent/ZA913879B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA913879A 1990-05-22 1991-05-22 Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy ZA913879B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/527,227 US5165922A (en) 1990-05-22 1990-05-22 Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy

Publications (1)

Publication Number Publication Date
ZA913879B true ZA913879B (en) 1992-03-25

Family

ID=24100637

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913879A ZA913879B (en) 1990-05-22 1991-05-22 Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy

Country Status (7)

Country Link
US (1) US5165922A (de)
EP (1) EP0575321A1 (de)
JP (1) JPH05508630A (de)
CA (1) CA2083391A1 (de)
HU (1) HUT63340A (de)
WO (1) WO1991017770A1 (de)
ZA (1) ZA913879B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733752B1 (en) * 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
NZ332588A (en) * 1996-05-15 2000-11-24 Altarex Inc Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
US6410041B1 (en) * 1998-04-28 2002-06-25 Trustees Of Tufts College Culturing cells in presence of amphipathic weak bases and/or cations and multiple drug resistance inhibitor containing reserpine
EP1085905B1 (de) * 1998-06-15 2010-09-08 Quest Pharmatech Inc. Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
CN1689646A (zh) * 1998-08-11 2005-11-02 拜奥根Idec公司 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法
CA2350064C (en) * 1998-11-09 2012-05-08 Idec Pharmaceuticals Corporation Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
DK1169021T3 (da) * 1999-04-01 2010-01-11 Hana Biosciences Inc Sammensætninger og fremgangsmåder til behandling af lymfom
US7244450B2 (en) * 1999-04-01 2007-07-17 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
KR100881471B1 (ko) * 2000-05-08 2009-02-05 셀덱스 쎄라퓨틱스, 인크. 수상세포에 대한 인간 모노클로날 항체
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
JP4463475B2 (ja) * 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents
AU2003223600A1 (en) * 2002-04-11 2003-10-27 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
US20090074757A1 (en) * 2005-04-08 2009-03-19 Enrico Pesenti Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors
EP2162152A2 (de) * 2007-06-01 2010-03-17 Biogen Idec MA, Inc. Cripto-bindende moleküle
CN101969970B (zh) 2007-10-12 2014-10-15 西雅图基因公司 用抗体-药物偶联物联合治疗
JP6320756B2 (ja) * 2010-12-06 2018-05-09 キュア キャンサー ワールドワイド エルエルシー 癌を治療するための化学および免疫療法を用いた癌細胞の代謝標的法
RU2655964C2 (ru) 2012-11-20 2018-05-30 Спектрум Фармасьютикалз, Инк. Улучшенный способ получения инкапсулированного в липосомы винкристина для терапевтического применения
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4693966A (en) * 1983-03-11 1987-09-15 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
US4906562A (en) * 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas

Also Published As

Publication number Publication date
HUT63340A (en) 1993-08-30
JPH05508630A (ja) 1993-12-02
CA2083391A1 (en) 1991-11-23
US5165922A (en) 1992-11-24
WO1991017770A1 (en) 1991-11-28
HU9203628D0 (en) 1993-04-28
EP0575321A1 (de) 1993-12-29
EP0575321A4 (de) 1993-07-12

Similar Documents

Publication Publication Date Title
ZA913879B (en) Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
EP0556285A4 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
NZ225675A (en) Treating lung conditions with gamma interferon and/or tumour necrosis factor
EP0428188A3 (en) Novel immunoconjugates and methods for their use in tumor therapy
ZA856118B (en) Treatment of cancer with phlorizin and its derivatives
ZA844377B (en) The effect of human tumor necrosis factor and human interferon and human cancer cells and methods
HUP0004326A3 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ZA871528B (en) The treatment of diseases of the immune system with diphenylhydantoin and its derivatives
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
GB2174391B (en) 5-pyrimidinecarboxamides and treatment of leukemia and tumours therewith
IL78869A0 (en) In vitro immunization of human splenocytes against tumor associated antigens
IT1198023B (it) Antibiotici peptidici ad attivita' antimicrobica ed antitumorale
EP0280593A3 (en) Composition on the basis of an amino-acid and vitamins for use in cancer therapy
AU9011891A (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
ZA93212B (en) Enzyme castration of animal and tumor treatment
NO931636D0 (no) Synergistisk terapi med kombinasjoner av anti-tumor antistoffer og biologisk aktive forbindelser
ZA881943B (en) Treatment of cancer with phlorizin and its derivatives
AU556770B2 (en) Novel tf substance having carcino static and immunostimulating activity
PL277241A1 (en) Agent stimulating growth of ruminants
IL89998A0 (en) Use of gonadoliberin derivatives in the treatment of tumours
GB2245475B (en) Improvements in the treatment of animal feeds
Rosberger The assessment and treatment of nausea and vomiting associated with cancer chemotherapy
IE882290L (en) Treatment of infections with tumor necrosis factor
ZA918336B (en) Udpg as a rescue agent in cancer therapy after the administration of antipyrimidine or related anti-tumor agents with or without bau
ZA899631B (en) Cancer treatment